利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy
    4.
    发明申请
    Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy 审中-公开
    CTLA-4阻断治疗CTLA-4多态性的评估

    公开(公告)号：US20060057626A1

    公开(公告)日：2006-03-16

    申请号：US11218284

    申请日：2005-08-31

    申请人： Geoffrey Nichol ,  Michael Yellin ,  Steven Fischkoff ,  Jeffrey Weber

    发明人： Geoffrey Nichol ,  Michael Yellin ,  Steven Fischkoff ,  Jeffrey Weber

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/142 ,  C12Q2600/156

    摘要： The invention provides methods for predicting responsiveness of a subject to therapy with a CTLA-4 blocking agent. The methods involve assaying for at least one CTLA-4 polymorphism in the subject and predicting responsiveness of the subject to therapy with a CTLA-4 blocking agent based on presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise selecting a treatment regimen with a CTLA-4 blocking agent in a subject based upon presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise administering a CTLA-4 blocking agent to the subject according to the selected treatment regimen. Kits comprising a CTLA-4 blocking agent and means for assaying one or more CTLA-4 polymorphisms, optionally including a vaccine, are also provided.

    摘要翻译： 本发明提供了用CTLA-4阻断剂预测受试者对治疗的反应性的方法。 所述方法包括测定受试者中至少一种CTLA-4多态性，并且基于受试者中CTLA-4多态性等位基因的存在或不存在，预测受试者与CTLA-4封闭剂治疗的反应性。 所述方法还可包括基于受试者中CTLA-4多态性等位基因的存在或不存在，在受试者中选择与CTLA-4封闭剂的治疗方案。 所述方法还可以包括根据所选择的治疗方案向受试者施用CTLA-4封闭剂。 还提供了包含CTLA-4封闭剂的试剂盒和用于测定一种或多种CTLA-4多态性（任选地包括疫苗）的方法。

    Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells
    7.
    发明申请
    Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells 审中-公开
    T-BAM（CD40L）技术治疗涉及平滑肌细胞疾病的治疗应用

    公开(公告)号：US20080050369A1

    公开(公告)日：2008-02-28

    申请号：US11698692

    申请日：2007-01-25

    申请人： Michael Yellin ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

    发明人： Michael Yellin ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

    IPC分类号： A61K39/395 ,  A61P1/02

    CPC分类号： C07K14/70575 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2319/00 ,  G01N33/5061 ,  G01N2333/70596

    摘要： Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the smooth muscle cells. Activation of smooth muscle cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an anti-T-BAM (CD40L) antibody capable of inhibiting the interaction between CD40 ligand and the smooth muscle cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells smooth muscle cells are treated, in particular inflammatory bowel disease.

    摘要翻译： 通过使平滑肌细胞与能够抑制CD40配体和携带CD40的平滑肌细胞之间的相互作用的抗T-BAM（CD40L）抗体接触来抑制CD40配体在其细胞表面上带有CD40的平滑肌细胞的活化， 其量有效抑制平滑肌细胞的活化。 通过向受试者施用能够抑制CD40配体和平滑肌细胞之间的相互作用的抗T-BAM（CD40L）抗体，以受体的CD40配体在其表面上带有CD40的平滑肌细胞的活化， 有效抑制细胞的活化。 治疗依赖于CD40配体诱导的含CD40细胞平滑肌细胞活化的病症，特别是炎症性肠病。